KTTA
Pasithea Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Pasithea Therapeutics reported positive interim Phase 1 data showing long-term safety and durable activity in advanced cancerJul 1, 2026
- Pasithea Therapeutics received FDA Rare Pediatric Disease Designation for PAS-004 in neurofibromatosis type 1Apr 20, 2026
- Pasithea received FDA Fast Track designation for PAS-004 in neurofibromatosis type 1Apr 1, 2026
- Pasithea Therapeutics announced completion of cohort 7 in ongoing Phase 1 trial of PAS-004 in advanced cancer patients, with positive safety, pharmacokinetic, and pharmacodynamic dataNov 24, 2025
- Pasithea Therapeutics announces positive Phase 1 data showing partial response, clinical activity, and favorable safety profile for PAS-004 in advanced cancerNov 21, 2025